SEARCH

SEARCH BY CITATION

References

  • Abildgaard, L., Ellebaek, E., Gustafsson, G., Abramsson, J., Hovi, L., Jonmundsson, G., Zeller, B. & Hasle, H. (2006) Optimal treatment intensity in children with Down syndrome and myeloid leukaemia; data from 56 children treated on NOPHO-AML protocols and a review of the literature. Annals of Hematology, 85, 275280.
  • Arlin, Z., Case, D.C., Moore, J., Wiernik, P., Feldman, E., Saletan, S., Desai, P., Sia, L. & Cartwright, K. (1990) Randomised multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia, 4, 177183.
  • Burnett, A.K., Hills, R., Milligan, D.W., Goldstone, A.H., Prentice, A.G., McMullin, M.-F., Duncombe, A., Gibson, B. & Wheatley, K. (2010) Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. Journal of Clinical Oncology, 28, 586595.
  • Creutzig, U., Zimmermann, M., Ritter, J., Reinhardt, D., Hermann, J., Henze, G., Jurgens, H., Kabisch, H., Reiter, A., Riehm, H., Gadner, H. & Schellong, G. (2005a) Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia, 19, 20302042.
  • Creutzig, U., Reinhardt, D., Diekamp, S., Dworzak, M., Stary, J. & Zimmermann, M. (2005b) AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukaemia, 19, 13551366.
  • Gibson, B.E.S., Wheatley, K., Hann, I.M., Stevens, R.F., Webb, D., Hills, R.K., de Graaf, S.S.N., Harrison, C.J.; for the UK Childhood Leukaemia Working Party and the Dutch Childhood Oncology Group. (2005) Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 19: 21302138.
  • Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. & Goldstone, A. (1999) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML10 trial. Blood, 92, 23222333.
  • Grimwade, D., Hills, R.K., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A.H., Wheatley, K., Harrison, C.J., Burnett, A.K.; on behalf of the National Cancer Research Institute Adult Leukaemia Working Group. (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. Blood, 116, 254265.
  • Harrison, C.J., Hills, R.K., Moorman, A.V., Grimwade, D., Hann, I., Webb, D.K.H., Stevens, R., Wheatley, K., de Graff, S.S.N., van Berg, E., Burnett, A.K. & Gibson, B.E.S. (2010) Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council trials AML10 and 12. Journal of Clinical Oncology, 28, 26742681.
  • Kalbfleisch, J.D. & Prentice, R. (1980) The Statistical Analysis of Failure Time Data. John Wiley & Sons, Hoboken, NJ, USA.
  • Lange, B.J., Smith, F.O., Feusner, J., Barnard, D.R., Dinndorf, P., Feig, S., Heerema, N.A., Arndt, C., Arceci, R.J., Seibel, N., Weiman, M., Dusenbery, K., Shannon, K., Luna-Fineman, S., Gerbing, R.B. & Alonzo, T.A. (2008) Outcomes in CCG-2961, a Children’s Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. Blood, 111, 10441053.
  • Lie, S.O., Abrahamsson, J., Clausen, N., Forestier, E., Hasle, H., Hovi, L., Jonmundsson, G., Mellander, L., Slimes, M.A., Yssing, M., Zeller, B. & Gustafsson, G. (2005) Long-term results in children with AML: NOPHO-AML Study Group – report of 3 consecutive trials. Leukemia, 19, 20902100.
  • Löwenberg, B., Suciu, S., Archimbaud, E., Haak, H., Stryckmans, P., de Cataldo, R., Dekker, A.W., Berneman, Z.N., Thyss, A., van der Lelle, J., Sonneveld, P., Visani, G., Fillet, G., Hayat, M., Hagemeijer, A., Solbu, G. & Zittoun, R. (1998) Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low dose cytarabine for maintenance of remission and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group. Journal of Clinical Oncology, 16, 872881.
  • Mandelle, F., Vignetti, M., Suciu, S., Stasi, R., Petti, M.-C., Meloni, G., Muus, P., Marmont, F., Marie, J.-P., Labar, B., Thomas, X., di Raimondi, F., Willemze, R., Liso, V., Ferrara, F., Baila, L., Fazi, P., Zittoun, R., Amadori, S. & de Witte, T. (2009) Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA groups study AML-10. Journal of Clinical Oncology, 32, 53975403.
  • Ohtake, S., Miyawaki, S., Fujita, H., Kiyoi, H., Shinagawa, K., Usui, N., Okumura, H., Miyamura, K., Nakaseko, C., Miyazaki, Y., Fujieda, A., Nagai, T., Yamane, T., Taniwaki, M., Takahashi, M., Yagasaki, F., Kimura, Y., Asou, N., Sakamaki, H., Handa, H., Honda, S., Ohnishi, K., Naoe, T. & Ohno, R. (2011) Randomized study of induction therapy comparing standard-dose idarubicin with high dose daunorubicin in adult patients with previously untreated acute myeloid leukemia. JALSG AML201 Study. Blood, 117, 22992300.
  • Rao, A., Hills, R.K., Stiller, C., Gibson, B.E., de Graaf, S.S., Hann, I.M., O’Marcaigh, A., Wheatley, K. & Webb, D.K. (2006) Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML10 and 12 trials. British Journal of Haematology, 132, 576583.
  • Riley, L., Hann, I.M., Wheatley, K. & Stevens, R.F. (1999) Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MRC Childhood Leukaemia Working Party. British Journal of Haematology, 106, 436444.
  • Rubnitz, J.E., Inaba, H., Dahl, G., Ribeiro, R.C., Bowman, W.P., Taub, J., Pounds, S., Razzouk, B.I., Lacayo, N.J., Cao, X., Meshinchi, S., Degar, B., Airewele, G., Raimondi, S.C., Onciu, M., Coustan-Smith, E., Downing, J.R., Leung, W., Pui, C.H. & Campana, D. (2010) Minimal residual disease directed therapy for childhood acute myeloid leukemia: results of the AML02 multicentre trial. Lancet Oncology, 11, 543552.
  • Smith, F.O., Alonzo, T.A., Gerbing, R.B., Woods, W.G., Arceci, R.J. & Children’s Cancer Group. (2005) Long-term results of children with acute myeloid leukaemia: a report of three consecutive Phase III studies by the Children’s Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukaemia, 19, 20542062.
  • Stevens, R.F., Hann, I.M., Wheatley, K. & Gray, R.G. (1998) Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council’s 10th AML trial. British Journal of Haematology, 101, 130140.
  • Testi, A.M., Biondi, A., Lo Coco, F., Moleti, M.L., Giona, F., Vignetti, M., Menna, G., Locatelli, F., Pession, A., Barisone, E., De Rossi, G., Diverio, D., Micalizzi, C., Arico, M., Basso, G., Foa, R. & Mandelli, F. (2005) GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood, 106, 447453.
  • The AML Collaborative Group. (1998) A systematic collaborative overview of randomised trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. British Journal of Haematology, 103, 100109.
  • Tomizawa, D., Tabuchi, K., Kinoshita, A., Hanada, R., Kigasawa, H., Tsukimoto, I. & Tsuchida, M. (2007) Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children’s Cancer Study Group. Pediatric Blood & Cancer, 49, 127132.
  • Tsukimoto, I., Tawa, A., Horibe, K., Tabuchi, K., Kigasawa, H., Tsuchida, M., Yabe, H., Nakayama, H., Kudo, K., Kobayashi, R., Hamamoto, K., Imaizumi, M., Morimoto, A., Tsuchiya, S. & Hanada, R. (2009) Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML cooperative group. Journal of Clinical Oncology, 27, 40074013.
  • Webb, D.K. (2005) Optimizing therapy for myeloid disorders of Down syndrome. British Journal of Haematology, 131, 37.
  • Webb, D.K., Harrison, G., Stevens, R.F., Gibson, B.G., Hann, I.M., Wheatley, K. & MRC Childhood Leukemia Working Party. (2001) Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML10 and 12 trials for acute myeloid leukaemia. Blood, 98, 17141720.
  • Wells, R.J., Woods, W.G., Buckley, J.D., Odom, L.F., Benjamin, D., Bernstein, I., Betcher, D., Feig, S., Kim, T., Ruymann, F., Smithson, W., Srivastava, A., Tannous, R., Buckley, C.M., Whitt, K., Wolff, L. & Lampkin, B.C. (1994) Treatment of newly diagnosed children and adolescents with acute myeloid leukaemia: a Children’s Cancer Group study. Journal of Clinical Oncology, 12, 23672377.
  • Wheatley, K., Burnett, A.K., Goldstone, A.H., Gray, R., Hann, I.M., Harrison, C.J., Rees, J.K., Stevens, R.F. & Walker, H. (1999) A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML10 trial. United Kingdom Medical Research Council’s Adult and Childhood Leukaemia Working Parties. British Journal of Haematology, 107, 6979.
  • World Health Organization. (1979) Handbook for Reporting Results of Cancer Treatment. World Health Organization, Geneva, Switzerland, 1522.